We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid, Automated Test Detects Gonorrhea and Determines Antibiotic Susceptibility

By LabMedica International staff writers
Posted on 24 May 2021
An inexpensive, portable diagnostic test that gives results in only 15 minutes is expected to revolutionize detection of sexually transmitted diseases such as gonorrhea.

Effective treatment of sexually transmitted diseases (STIs) - such as gonorrhea with more than 87 million cases worldwide each year - is limited by diagnostic methods that cannot deliver results rapidly while the patient is still in the clinic. More...
Currently gonorrhea is diagnosed by classical culture methods or with more advanced, but expensive and time consuming, nucleic acid-based techniques such as PCR.

To address the need for fast and affordable diagnostic tests for STIs, investigators at Johns Hopkins University (Baltimore, MD, USA) developed a portable, rapid, on-cartridge magnetofluidic purification and testing (PROMPT) polymerase chain reaction (PCR) test.

The PROMPT device uses an automated procedure to analyze swab samples of urethral or penile fluid. First, the swab sample is mixed with a solution of magnetic particles in a tube, and a drop of the mixture is loaded into a cartridge, which snaps into the device. The device transfers the magnetized particles to reagents in the cartridge, which carries out 40 PCR cycles before displaying the results on the screen of a cellphone. Probes in the cartridge enable the device to both identify the presence of Neisseria gonorrhoeae, the pathogen causing gonorrhea, as well as genotyping the pathogen for the DNA signature linked to resistance to the antimicrobial drug ciprofloxacin. Results are received in less than 15 minutes.

The PROMPT device was used to analyze penile swab samples from sexual health clinics in Baltimore, MD, USA (n = 66) and Kampala, Uganda (n = 151) with an overall sensitivity and specificity of 97.7% and 97.6%, respectively, for N. gonorrhoeae detection and 100% concordance with culture results for ciprofloxacin resistance.

"Our portable, inexpensive testing platform has the potential to change the game when it comes to diagnosing and enabling rapid treatment of sexually transmitted infections," said senior author Dr. Tza-Huei Wang, professor of mechanical engineering at Johns Hopkins University. "It ensures that patients are diagnosed on the spot, and treatment can begin immediately, improving clinical outcomes. This will be especially valuable in low-resource settings, where well-equipped laboratories are not always available to every patient."

The PROMPT device for rapid diagnosis of gonorrhea was described in the May 12, 2021, online edition of the journal Science Translational Medicine.

Related Links:
Johns Hopkins University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.